Repros Therapeutics Inc., located in The Woodlands, Texas, met with the FDA to discuss clinical development of Proellex-V (telapristone). Proellex-V is a product that is administered to the vagina to treat uterine fibroids.
http://bionews-tx.com/news/2013/05/24/repros-therapeutics-gets-fda-ok-for-phase-2b-trial-of-proellexr-v/
No comments:
Post a Comment